Can I read Virus-Like Particles as an Immunogenic Platform for Cancer Vaccines on EtoBox?

Virus-Like Particles as an Immunogenic Platform for Cancer Vaccines by Caldeira, Jerri C.; Perrine, Michael; Pericle, Federica; Cavallo, Federica is a Medicine article available to read on EtoBox.

What is Virus-Like Particles as an Immunogenic Platform for Cancer Vaccines about?

Virus-like particles (VLP) spontaneously assemble from viral structural proteins. They are naturally biocompatible and non-infectious. VLP can serve as a platform for many potential vaccine epitopes, display them in a dense repeating array, and elicit antibodies against non-immunogenic substances, including tumor-associated self-antigens. Genetic or chemical conjugation facilitates the multivalent display of a homologous or heterologous epitope. Most VLP range in diameter from 25 to 100 nm and, in most cases, drain freely into the lymphatic vessels and induce antibodies with high titers and affinity without the need for additional adjuvants. VLP administration can be performed using different strategies, regimens, and doses to improve the immunogenicity of the antigen they expose on their surface. This article summarizes the features of VLP and presents them as a relevant platform technology to address not only infectious diseases but also chronic diseases and cancer.

Who reads Virus-Like Particles as an Immunogenic Platform for Cancer Vaccines?

Author

Caldeira, Jerri C.; Perrine, Michael; Pericle, Federica; Cavallo, Federica

Publisher

MDPI AG; Multidisciplinary Digital Publishing Institute (MDPI); Basel: MDPI, 2009- (ISSN 1999-4915)

Published

2020

Language

EN

Field

Medicine (Health Sciences)